UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.
UnitedHealthcare's decision to exclude Lantus in favor of Basaglar begs the question of how low biosimilar pricing will go, amid soaring diabetes costs.